Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 1
2016 2
2017 1
2019 2
2020 1
2021 4
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.
Maity TK, Kim EY, Cultraro CM, Venugopalan A, Khare L, Poddutoori R, Marappan S, Syed SD, Telford WG, Samajdar S, Ramachandra M, Guha U. Maity TK, et al. Among authors: cultraro cm. Cancers (Basel). 2023 Apr 12;15(8):2263. doi: 10.3390/cancers15082263. Cancers (Basel). 2023. PMID: 37190191 Free PMC article.
LKB1 acts as a critical brake for the glucagon-mediated fasting response.
Acevedo-Acevedo S, Stefkovich ML, Kang SWS, Cunningham RP, Cultraro CM, Porat-Shliom N. Acevedo-Acevedo S, et al. Among authors: cultraro cm. Hepatol Commun. 2022 Aug;6(8):1949-1961. doi: 10.1002/hep4.1942. Epub 2022 Mar 31. Hepatol Commun. 2022. PMID: 35357082 Free PMC article.
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA, Maity TK, Cultraro CM, Misra V, Zhang X, Ade C, Gao S, Milewski D, Nguyen KD, Ebrahimabadi MH, Hanada KI, Khan J, Sahinalp C, Yang JC, Guha U. Qi YA, et al. Among authors: cultraro cm. Mol Cell Proteomics. 2021;20:100136. doi: 10.1016/j.mcpro.2021.100136. Epub 2021 Aug 13. Mol Cell Proteomics. 2021. PMID: 34391887 Free PMC article.
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Kim C, Xi L, Cultraro CM, Wei F, Jones G, Cheng J, Shafiei A, Pham TH, Roper N, Akoth E, Ghafoor A, Misra V, Monkash N, Strom C, Tu M, Liao W, Chia D, Morris C, Steinberg SM, Bagheri H, Wong DTW, Raffeld M, Guha U. Kim C, et al. Among authors: cultraro cm. Cancers (Basel). 2021 Jul 3;13(13):3342. doi: 10.3390/cancers13133342. Cancers (Basel). 2021. PMID: 34283064 Free PMC article.
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, Pitts S, Keswani M, Gao S, Nguyen KDP, Cowart J, Kirkali F, Wu C, Guha U. Zhang X, et al. Among authors: cultraro cm. Cancer Res. 2021 Jun 1;81(11):3051-3066. doi: 10.1158/0008-5472.CAN-20-2435. Epub 2021 Mar 16. Cancer Res. 2021. PMID: 33727228 Free PMC article.
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, El Meskini R, Ohler ZW, Maity TK, Venugopalan A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Panchenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Roper N, et al. Among authors: cultraro cm. Cell Rep Med. 2020 Apr 21;1(1):100007. doi: 10.1016/j.xcrm.2020.100007. Cell Rep Med. 2020. PMID: 32483558 Free PMC article. Clinical Trial.
18 results